메뉴 건너뛰기




Volumn 4, Issue 4, 2013, Pages 361-369

Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer

Author keywords

CA19 9; Chemoradiotherapy (CRT); Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL;

EID: 84995812319     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.045     Document Type: Article
Times cited : (34)

References (17)
  • 1
    • 27944441699 scopus 로고    scopus 로고
    • Multimodality approaches for pancreatic cancer
    • Yang GY, Wagner TD, Fuss M, et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352-67.
    • (2005) CA Cancer J Clin , vol.55 , pp. 352-367
    • Yang, G.Y.1    Wagner, T.D.2    Fuss, M.3
  • 2
    • 84868152970 scopus 로고    scopus 로고
    • Pancreatic cancer: current standards, research updates and future directions
    • Hsueh CT. Pancreatic cancer: current standards, research updates and future directions. J Gastrointest Oncol 2011;2:123-5.
    • (2011) J Gastrointest Oncol , vol.2 , pp. 123-125
    • Hsueh, C.T.1
  • 3
    • 33745552215 scopus 로고    scopus 로고
    • Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    • Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-902.
    • (2006) J Clin Oncol , vol.24 , pp. 2897-2902
    • Ferrone, C.R.1    Finkelstein, D.M.2    Thayer, S.P.3
  • 4
    • 58049202340 scopus 로고    scopus 로고
    • Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704
    • Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.
    • (2008) J Clin Oncol , vol.26 , pp. 5918-5922
    • Berger, A.C.1    Garcia Jr., M.2    Hoffman, J.P.3
  • 5
    • 77649280747 scopus 로고    scopus 로고
    • CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis
    • Tsavaris N, Kosmas C, Papadoniou N, et al. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother 2009;21:673-80.
    • (2009) J Chemother , vol.21 , pp. 673-680
    • Tsavaris, N.1    Kosmas, C.2    Papadoniou, N.3
  • 6
    • 0032076257 scopus 로고    scopus 로고
    • Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy
    • Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:393-6.
    • (1998) Int J Radiat Oncol Biol Phys , vol.41 , pp. 393-396
    • Katz, A.1    Hanlon, A.2    Lanciano, R.3
  • 7
    • 38549176328 scopus 로고    scopus 로고
    • CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
    • Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-8.
    • (2008) Lancet Oncol , vol.9 , pp. 132-138
    • Hess, V.1    Glimelius, B.2    Grawe, P.3
  • 8
    • 0034009704 scopus 로고    scopus 로고
    • Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
    • Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-6.
    • (2000) Br J Cancer , vol.82 , pp. 1013-1016
    • Halm, U.1    Schumann, T.2    Schiefke, I.3
  • 9
    • 84995748195 scopus 로고    scopus 로고
    • The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
    • Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105-19.
    • (2012) J Gastrointest Oncol , vol.3 , pp. 105-119
    • Ballehaninna, U.K.1    Chamberlain, R.S.2
  • 10
    • 0041564101 scopus 로고    scopus 로고
    • Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy
    • Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003;57:90-7.
    • (2003) Int J Radiat Oncol Biol Phys , vol.57 , pp. 90-97
    • Micke, O.1    Bruns, F.2    Kurowski, R.3
  • 11
    • 61349202170 scopus 로고    scopus 로고
    • CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy
    • Koom WS, Seong J, Kim YB, et al. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73:1148-54.
    • (2009) Int J Radiat Oncol Biol Phys , vol.73 , pp. 1148-1154
    • Koom, W.S.1    Seong, J.2    Kim, Y.B.3
  • 13
    • 0030968481 scopus 로고    scopus 로고
    • Comparing two diagnostic tests against the same "gold standard" in the same sample
    • Bloch DA. Comparing two diagnostic tests against the same "gold standard" in the same sample. Biometrics 1997;53:73-85.
    • (1997) Biometrics , vol.53 , pp. 73-85
    • Bloch, D.A.1
  • 14
    • 77649159782 scopus 로고    scopus 로고
    • Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival
    • Takahashi H, Ohigashi H, Ishikawa O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9.
    • (2010) Ann Surg , vol.251 , pp. 461-469
    • Takahashi, H.1    Ohigashi, H.2    Ishikawa, O.3
  • 15
    • 0042418394 scopus 로고    scopus 로고
    • Utility of tumor markers in determining resectability of pancreatic cancer
    • discussion 955-6
    • Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-5; discussion 955-6.
    • (2003) Arch Surg , vol.138 , pp. 951-955
    • Schlieman, M.G.1    Ho, H.S.2    Bold, R.J.3
  • 16
    • 0021027153 scopus 로고
    • Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
    • Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-92.
    • (1983) Cancer Res , vol.43 , pp. 5489-5492
    • Magnani, J.L.1    Steplewski, Z.2    Koprowski, H.3
  • 17
    • 33846908072 scopus 로고    scopus 로고
    • Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
    • Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31.
    • (2007) J Clin Oncol , vol.25 , pp. 326-331
    • Huguet, F.1    André, T.2    Hammel, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.